General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is ...

DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

The risk of dying from the most common form of primary liver cancer is approximately 30% higher for patients with low ...

Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection ...

In early-stage HCC patients (BCLC 0 and A), CP mRNA was elevated in 67.9% of cases, outperforming AFP, which detected only 46 ...

Among patients with hepatocellular carcinoma, MAFLD was not an independent predictor for overall survival or progression-free survival.

Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.